| Metric | Q3-26 | Q3-25 |
|---|---|---|
| Revenue | 1,024 | 956.05 |
| Pretax Income | 32.22 | 5.67 |
| Net Income | 12.95 | 0.37 |
| Diluted EPS | 0.26 | 0.01 |
- Net Income YoY
- +3,372.4%
Key highlights
- Revenue reached $1,024 million, a 7.1% increase compared to $956.05 million in Q3 2025
- Net income soared 3,372.4% year-over-year to $12.95 million
- Pretax income improved to $32.22 million from $5.67 million in the prior-year period
- Diluted EPS rose to $0.26, up from $0.01 in the third quarter of 2025
- Net receivables increased to $530.9 million as of September 30, 2026
How the Period Went
Astrana Health achieved a notable scale milestone in the third quarter of 2026, with revenue climbing to $1,024 million from $956.05 million a year earlier. This top-line expansion was accompanied by a dramatic shift in the bottom line, as net income rose 3,372.4% to $12.95 million, compared to $0.37 million in the same period last year. This surge in profitability primarily reflects the stabilization of medical cost trends and the increased contribution from full-risk capitation contracts. Diluted EPS followed this trajectory, reaching $0.26 for the quarter, while pretax income nearly sextupled to $32.22 million, highlighting improved operating leverage across the company's physician networks.
Margins and Profitability
Profitability during the quarter was bolstered by the maturation of the company's Care Partners segment, which benefited from favorable risk-adjustment sweeps and improved clinical outcomes. While net income reached $12.95 million, the company's balance sheet reflected a decrease in cash to $396.2 million from year-end 2025 levels. Simultaneously, net receivables rose significantly to $530.9 million, suggesting higher billing activity from capitated arrangements. The company's P/E ratio of 47.0 reflects market expectations of continued earnings growth following this period of margin expansion. Management noted that medical cost performance improved organically, particularly in expansion markets like Texas, helping to offset persistent Medicaid membership attrition.
Business Overview
- Operates a physician-centric, technology-powered healthcare platform focused on value-based care delivery
- The Care Partners segment manages a network of aligned providers under capitated risk arrangements
- The Care Delivery segment provides direct primary and specialty care through physical clinical sites
- The Care Enablement segment offers the technology and administrative infrastructure for population health management
- Serves approximately 1.5 million patients across Medicare, Medicaid, and commercial health plans
Financial Context and Industry Landscape
The quarterly performance occurs amidst a challenging broader healthcare environment characterized by rising medical utilization and high pharmacy costs, particularly for GLP-1 medications. Astrana's 9.36% quarterly share price gain outpaced some peers as the market reacted to its ability to manage medical loss ratios effectively. With a market capitalization of $2.18 billion and an RSI of 58.9, the stock remains in a neutral technical position. The company's shift toward full-risk arrangements, which are expected to account for 82% of capitation revenue by year-end, aligns with industry-wide efforts to move toward outcome-based reimbursement models in the face of rising 2027 medical cost projections.
Down 15.7% since our story on 6 Nov: $39.01 when we broke it → $32.87 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $36.90 |
|---|---|
| 20 Oct | $38.58 |
| 21 Oct | $37.35 |
| 22 Oct | $38.01 |
| 23 Oct | $37.45 |
| 26 Oct | $37.23 |
| 27 Oct | $36.94 |
| 28 Oct | $36.67 |
| 29 Oct | $36.62 |
| 30 Oct | $36.53 |
| 2 Nov | $36.88 |
| 3 Nov | $36.73 |
| 4 Nov | $39.67 |
| 5 Nov | $39.01 |
| 6 Nov | $34.50 |
| 9 Nov | $33.77 |
| 10 Nov | $32.18 |
| 11 Nov | $32.94 |
| 12 Nov | $31.77 |
| 13 Nov | $31.80 |
| 16 Nov | $32.87 |
| Date | Announcement | Amount |
|---|---|---|
| 05 Nov 2026 | Q3 2026 total revenueSource: prnewswire.com | $1.02 Billion |
| 05 Nov 2026 | FY 2026 revenue guidance (narrowed)Source: stocktitan.net | – |
| 06 Aug 2026 | Q2 2026 total revenueSource: ir.astranahealth.com | $972.5 Million |
| 06 Aug 2026 | FY 2026 revenue guidanceSource: stocktitan.net | – |
| 07 May 2026 | Q1 2026 total revenueSource: prnewswire.com | $965.1 Million |
| 02 Mar 2026 | FY 2025 total revenueSource: prnewswire.com | $3.18 Billion |
Management commentary
“Our third quarter results demonstrate the growing impact of Astrana's physician-centric, AI-native healthcare operating platform and our team's continued focus on execution.”
| Share price | $39.01 |
|---|---|
| Market cap | $2.2B |
| Revenue (annual) | $3.2B |
| P/E (TTM) | 47.0× |
| 1-month price change | +5.43% |
| Sector | HealthcareMedical Care Facilities |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Astrana Health, Inc. announcing its financial results for the quarter ended September 30, 2026.
Track Astrana Health, Inc. live
Get the next Astrana Health, Inc. SEC filing seconds after it lands.



